Navigation Links
Solving the 50-year-old puzzle of thalidomide
Date:11/17/2009

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments for Leprosy, Crohn's Disease, AIDS and some forms of cancer.

Thalidomide was used in over 46 countries following its launch in 1957, but its side effects led to over 10000 children being born with birth defects and the drug was subsequently banned in 1962. However, the drug is now experiencing a renaissance worldwide, particularly across Africa and South America where new cases of thalidomide-induced limb defects are now occurring. This, argues Dr Neil Vargesson of the University of Aberdeen, raises the urgency for research which can target and isolate the drug's negative side effects.

"The mere mention of thalidomide instils fear in some people to this day as it caused the biggest medical disaster in history," said Vargesson. "However it still raises hopes for the treatments of diseases such as Leprosy and multiple myeloma."

Dr Vargesson and his team were the first to demonstrate how the drug causes limb defects by targeting immature blood vessels and now this latest article attempts to link all previous models of thalidomide action together to create one central model. This model proposes that all thalidomide associated defects could be caused by the same 'common mechanism', primarily an effect on angiogenesis, the growth of new blood vessels.

The understanding that the drug's targeting of blood vessels is a 'common mechanism' and the root cause of thalidomide's other side effects raises the possibility of producing a safer form of the drug which can isolate this mechanism and retain clinical benefits.

"Understanding this mechanism resolves a 50-year-old puzzle," concluded Vargesson, "it answers the questions asked by scientists since the first cases were identified in 1958. The possibility of producing analogues of the drug for targeting specific conditions without the devastating side effects is now a very real possibility."


'/>"/>

Contact: Ben Norman
Benorman@wiley.com
44-124-377-0375
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Celiac Disease Provides Clues To Solving Autoimmunity
2. Study finds autistics better at problem-solving
3. MonoSol Rx Announces FDA Acceptance of NDA for Ondansetron Orally Dissolving Film Strip
4. Body movements can influence problem solving, researchers report
5. MonoSol Rx and Strativa Pharmaceuticals Submit New Drug Application for Ondansetron Orally Dissolving Film Strip
6. Study shows potential for resolving type 2 diabetes with bariatric surgery
7. Eating Disorder International Symposium - Shoreline Center for Eating Disorder Treatment and Eating Disorder Awareness Week, Converge on Solving the Life-Threatening Illness
8. Resolving to Break an Addictive Habit?
9. New Strategies for the New Year: Resolving to break an addiction? Help from Harvard Medical School
10. Prevention is the Key to Solving Health Care Crisis;
11. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
Breaking Medicine Technology: